What adverse reactions happened during this study?
The most common adverse reaction was a headache. This adverse reaction happened in 2.3% of the participants who took acalabrutinib and BSC. This was 2 out of 86 participants. There were other adverse reactions, but these happened in 1 participant each.

How has this study helped patients and researchers?
This study helped researchers learn more about how acalabrutinib works and about its safety in participants with COVID-19 who need hospital care. Researchers look at the results of many studies to decide which treatments work best and are safest. This summary shows only the main results from this one study. Other studies may provide new information or different results. Further clinical studies with acalabrutinib in the treatment of COVID-19 are not planned.